Claire N Harrison

List of Publications by Citations

168 papers	9,905 citations	43 h-index	98 g-index
185 ext. papers	11,907 ext. citations	6.1 avg, IF	5.88 L-index

#	Paper	IF	Citations
168	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *New England Journal of Medicine*, **2012**, 366, 787-98	59.2	1232
167	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *New England Journal of Medicine*, **2007**, 356, 459-68	59.2	996
166	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *Journal of Clinical Oncology*, **2011**, 29, 761-70	2.2	589
165	Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *New England Journal of Medicine*, **2015**, 372, 426-35	59.2	533
164	Effect of mutation order on myeloproliferative neoplasms. *New England Journal of Medicine*, **2015**, 372, 601-612	59.2	334
163	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. *British Journal of Haematology*, **2005**, 130, 174-95	4.5	264
162	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*, **2018**, 32, 1057-1069	10.7	263
161	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. *New England Journal of Medicine*, **2018**, 379, 1416-1430	59.2	256
160	Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. *Journal of Clinical Oncology*, **2012**, 30, 4098-103	2.2	252
159	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncology*, **2015**, 1, 643-51	13.4	242
158	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*, **2013**, 122, 1395-8	2.2	218
157	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*, **2011**, 118, 401-8	2.2	215
156	Guideline for investigation and management of adults and children presenting with a thrombocytosis. *British Journal of Haematology*, **2010**, 149, 352-75	4.5	209
155	Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. *Blood*, **2008**, 111, 60-70	2.2	187
154	The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. *Leukemia Research*, **2009**, 33, 1199-203	2.7	173
153	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood*, **2013**, 121, 4778-81	2.2	159
152	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. *Haematologica*, **2015**, 100, 1139-45	6.6	151

151	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematology,the*, **2017**, 4, e317-e324	14.6	148
150	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *Lancet Haematology,the*, **2017**, 4, e225-e236	14.6	137
149	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *Journal of Hematology and Oncology*, **2017**, 10, 156	22.4	137
148	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 652-659	13.4	133
147	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. *Nature Communications*, **2015**, 6, 6691	17.4	120
146	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. *Lancet Haematology,the*, **2018**, 5, e73-e81	14.6	115
145	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. *British Journal of Haematology*, **2010**, 148, 961-3	4.5	115
144	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. *Haematologica*, **2016**, 101, 821-9	6.6	115
143	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. *Blood*, **2017**, 130, 1889-1897	2.2	101
142	Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. *British Journal of Haematology*, **2005**, 129, 293-306	4.5	101
141	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. *Haematologica*, **2016**, 101, 926-31	6.6	91
140	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. *British Journal of Haematology*, **2007**, 138, 821-2	4.5	90
139	Guideline for the diagnosis and management of myelofibrosis. *British Journal of Haematology*, **2012** , 158, 453-71	4.5	76
138	Essential thrombocythaemia: challenges and evidence-based management. *British Journal of Haematology*, **2005**, 130, 153-65	4.5	75
137	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. *British Journal of Haematology*, **2013**, 160, 25-34	4.5	68
136	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. *Blood*, **2014**, 123, 3803-10	2.2	65
135	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. *British Journal of Haematology*, **2013**, 162, 229-39	4.5	60
134	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. *British Journal of Haematology*, **2019**, 184, 176-191	4.5	60

133	JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. *British Journal of Haematology*, **2015**, 171, 60-73	4.5	59
132	A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. *British Journal of Haematology*, **2013**, 162, 498-508	4.5	58
131	Immunological Consequences of JAK Inhibition: Friend or Foe?. *Current Hematologic Malignancy Reports*, **2015**, 10, 370-9	4.4	56
130	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. *Annals of Hematology*, **2017**, 96, 1653-1665	3	49
129	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. *British Journal of Haematology*, **2019**, 184, 161-175	4.5	47
128	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *American Journal of Hematology*, **2020**, 95, 594-603	7.1	45
127	Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. *British Journal of Haematology*, **2016**, 175, 31-6	4.5	45
126	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia*, **2021**, 35, 485-493	10.7	45
125	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. *Journal of Clinical Oncology*, **2016**, 34, 151-9	2.2	42
124	The management and outcome of 18 pregnancies in women with polycythemia vera. *Haematologica* , **2005**, 90, 1477-83	6.6	41
123	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. *Haematologica*, **2019**, 104, 659-668	6.6	40
122	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. *Haematologica*, **2018**, 103, 51-60	6.6	39
121	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. *Therapeutic Advances in Hematology*, **2012**, 3, 341-54	5.7	36
120	Current trends in essential thrombocythaemia. *British Journal of Haematology*, **2002**, 117, 796-808	4.5	36
119	Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. *Haematologica*, **2016**, 101, e182-4	6.6	36
118	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. *Haematologica*, **2014**, 99, 292-8	6.6	35
117	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. *Blood*, **2019**, 134, 557-557	2.2	35
116	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). *Blood*, **2018**, 132, 577-577	2.2	32

115	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. *Journal of Clinical Oncology*, **2018**, 36, 3361-3369	2.2	32
114	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia. *Haematologica*, **2017**, 102, e238-e240	6.6	31
113	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. *British Journal of Haematology*, **2014**, 167, 421-3	4.5	30
112	Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. *British Journal of Haematology*, **2014**, 167, 418-20	4.5	30
111	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. *Blood*, **2019**, 134, 670-670	2.2	30
110	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. *Blood*, **2019**, 134, 671-671	2.2	30
109	Management of myelofibrosis after ruxolitinib failure. *Annals of Hematology*, **2020**, 99, 1177-1191	3	29
108	Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. *Thrombosis Research*, **2014**, 134, 251-4	8.2	27
107	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. *American Journal of Hematology*, **2020**, 95, 156-166	7.1	27
106	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. *Leukemia*, **2021**, 35, 3573-3577	10.7	26
105	Practical management of patients with myelofibrosis receiving ruxolitinib. *Expert Review of Hematology*, **2013**, 6, 511-23	2.8	24
104	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. *British Journal of Haematology*, **2021**, 194, 999-1006	4.5	24
103	Essential thrombocythemia. *Hematology/Oncology Clinics of North America*, **2003**, 17, 1175-90, vii	3.1	23
102	Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. *Haematologica*, **2019**, 104, 1580-1588	6.6	22
101	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. *Leukemia Research*, **2013**, 37, 162-8	2.7	22
100	Myeloproliferative disorders in pregnancy. *Hematology/Oncology Clinics of North America*, **2011**, 25, 261-75, vii	3.1	22
99	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. *Blood*, **2015**, 126, 825-825	2.2	22
98	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. *Haematologica*, **2019**, 104, 947-954	6.6	22

97	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. *Expert Review of Hematology*, **2017**, 10, 617-625	2.8	21
96	How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. *British Journal of Haematology*, **2020**, 189, 625-634	4.5	20
95	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2016**, 128, 479-479	2.2	20
94	Safety evaluation of ruxolitinib for treating myelofibrosis. *Expert Opinion on Drug Safety*, **2014**, 13, 967-76	4.1	19
93	Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. *British Journal of Haematology*, **2020**, 189, e79-e81	4.5	18
92	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. *British Journal of Haematology*, **2012**, 157, 426-37	4.5	18
91	Management of polycythaemia vera: a critical review of current data. *British Journal of Haematology*, **2016**, 172, 337-49	4.5	18
90	Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 129-34	3.1	17
89	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients. *Blood*, **2019**, 134, 4164-4164	2.2	17
88	Current and future status of JAK inhibitors. *Lancet, The*, **2021**, 398, 803-816	40	17
87	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. *Blood*, **2020**, 136, 49-50	2.2	15
86	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. *Leukemia Research*, **2017**, 56, 52-59	2.7	13
85	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. *Leukemia and Lymphoma*, **2016**, 57, 2259-67	1.9	13
84	How we diagnose and treat essential thrombocythaemia. *British Journal of Haematology*, **2015**, 171, 306-24	4.5	12
83	Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?. *British Journal of Haematology*, **2015**, 170, 323-35	4.5	12
82	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. *Future Oncology*, **2021**, 17, 1449-1458	3.6	11
81	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. *Current Hematologic Malignancy Reports*, **2016**, 11, 356-67	4.4	10
80	MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. *Blood*, **2020**, 136, 43-43	2.2	10

79	Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *British Journal of Haematology*, **2021**, 193, 692-696	4.5	10
78	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. *Leukemia*, **2021**, 35, 2989-2993	10.7	10
77	Bone marrow niche dysregulation in myeloproliferative neoplasms. *Haematologica*, **2020**, 105, 1189-1206	6.6	9
76	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. *Blood*, **2019**, 134, 2107-2111	2.2	9
75	What is pre-fibrotic myelofibrosis and how should it be managed in 2018?. *British Journal of Haematology*, **2018**, 183, 23-34	4.5	9
74	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.. *Journal of Clinical Oncology*, **2022**, JCO2102188	2.2	9
73	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. *Future Oncology*, **2018**, 14, 137-150	3.6	8
72	Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. *British Journal of Haematology*, **2021**, 193, 150-154	4.5	8
71	Current and future therapies for myelofibrosis. *Blood Reviews*, **2020**, 42, 100715	11.1	7
70	Current and future role of fedratinib in the treatment of myelofibrosis. *Future Oncology*, **2020**, 16, 175-186	3.6	7
69	Reply to J. Thiele et al. *Journal of Clinical Oncology*, **2009**, 27, e222-e223	2.2	7
68	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. *Blood*, **2011**, 118, 582-582	2.2	7
67	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. *Annals of Hematology*, **2021**, 1	3	7
66	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. *British Journal of Haematology*, **2021**, 195, 244-248	4.5	7
65	Pacritinib: a new agent for the management of myelofibrosis?. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 2381-90	4	6
64	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. *Blood*, **2018**, 132, 3032-3032	2.2	6
63	Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. *British Journal of Haematology*, **2016**, 175, 37-42	4.5	6
62	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.. *Lancet Haematology,the*, **2022**, 9, e301-e311	14.6	6

61	Facing erythrocytosis: Results of an international physician survey. *American Journal of Hematology*, **2019**, 94, E225-E227	7.1	5
60	Essential thrombocythaemia treated with recombinant interferon: "real world" United Kingdom referral centre experience. *British Journal of Haematology*, **2019**, 186, 561-564	4.5	5
59	How many JAK inhibitors in myelofibrosis?. *Best Practice and Research in Clinical Haematology*, **2014**, 27, 187-95	4.2	5
58	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. *British Journal of Haematology*, **2021**, 192, 62-74	4.5	5
57	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. *Cancer Medicine*, **2020**, 9, 8301-8309	4.8	5
56	Ruxolitinib for the Treatment of Essential Thrombocythemia. *HemaSphere*, **2018**, 2, e56	0.3	5
55	UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN. *British Journal of Haematology*, **2019**, 186, e1-e4	4.5	4
54	Anagrelide for control of thrombocytosis due to myeloproliferative disorders. *Future Oncology*, **2005**, 1, 609-18	3.6	4
53	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. *ESMO Open*, **2022**, 7, 100403	6	4
52	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. *Blood*, **2020**, 136, 46-47	2.2	4
51	The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. *Blood*, **2011**, 118, 3839-3839	2.2	4
50	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. *Blood*, **2016**, 128, 3117-3117	2.2	4
49	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial. *Blood*, **2021**, 138, 389-389	2.2	4
48	SOHO State-of-the-Art Update and Next Questions: MPN. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 1-12	2	4
47	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. *Lancet Haematology,the*, **2021**, 8, e658-e665	14.6	4
46	Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. *British Journal of Haematology*, **2020**, 191, 21-36	4.5	3
45	Molecular classification of myeloproliferative neoplasms-pros and cons. *Current Hematologic Malignancy Reports*, **2013**, 8, 342-50	4.4	3
44	Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?. *Journal of Cellular and Molecular Medicine*, **2013**, 17, 1410-4	5.6	3

43	Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 283-8	5.3	3
42	Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]. *Blood*, **2020**, 136, 2-3	2.2	3
41	Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.. *Blood*, **2007**, 110, 677-677	2.2	3
40	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. *Journal of Clinical Oncology*, **2014**, 32, 7022-7022	2.2	3
39	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. *Blood Advances*, **2020**, 4, 3063-3071	7.8	3
38	provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. *ELife*, **2021**, 10,	8.9	3
37	Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. *Blood*, **2020**, 136, 10-12	2.2	2
36	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). *Blood*, **2021**, 138, 3643-3643	2.2	2
35	Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations. *Haematologica*, **2018**, 103, e234-e236	6.6	2
34	Hb Baden: a rare high affinity haemoglobin variant and its management. *Journal of Clinical Pathology*, **2018**, 71, 79-80	3.9	2
33	Orphan drugs for myelofibrosis. *Expert Opinion on Orphan Drugs*, **2014**, 2, 391-405	1.1	1
32	Do we know more about essential thrombocythemia because of JAK2V617F?. *Current Hematologic Malignancy Reports*, **2009**, 4, 25-32	4.4	1
31	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. *Blood*, **2018**, 132, 4289-4289	2.2	1
30	The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells. *Blood*, **2020**, 136, 37-38	2.2	1
29	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. *Blood*, **2012**, 120, 889-889	2.2	1
28	Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre. *British Journal of Haematology*, **2021**, 193, 792-797	4.5	1
27	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. *HemaSphere*, **2021**, 5, e553	0.3	1
26	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms		1

25	Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021. *HemaSphere*, **2021**, 5, e609	0.3	1
24	Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. *Genome Research*, **2021**, 31, 1381-1394	9.7	1
23	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. *British Journal of Haematology*, **2018**, 182, 279-284	4.5	1
22	Clonality in essential thrombocythaemia. *Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology*, **2004**, 10, 184-7		1
21	A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK. *British Journal of Haematology*, **2020**, 188, e105-e109	4.5	0
20	Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies. *Blood*, **2021**, 138, 1505-1505	2.2	0
19	Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.. *Current Research in Translational Medicine*, **2022**, 70, 103338	3.7	0
18	How We Treat Myeloproliferative Neoplasms. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15 Suppl, S19-26	2	
17	A discussion of blood cancers and the MPN landmark survey. *International Journal of Hematologic Oncology*, **2017**, 6, 101-104	1	
16	Is there a role for pomalidomide in the treatment of myelofibrosis?. *Expert Opinion on Orphan Drugs* , **2016**, 4, 501-509	1.1	
15	Essential thrombocythaemia. *Hematology*, **2015**, 20, 119-20	2.2	
14	Update in the myeloproliferative neoplasms. *Clinical Medicine*, **2014**, 14 Suppl 6, s66-70	1.9	
13	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. *Blood*, **2020**, 136, 43-44	2.2	
12	A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol.. *PLoS ONE*, **2022**, 17, e0263195	3.7	
11	Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease. *Blood*, **2021**, 138, 2545-2545	2.2	
10	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. *Blood*, **2021**, 138, 2576-2576	2.2	
9	The Presence of the V617F Mutation Is Associated with Higher Haemoglobin, Older Age and an Increased Risk of Thrombosis in Essential Thrombocythemia.. *Blood*, **2005**, 106, 3531-3531	2.2	
8	The Use of the PFA-100 and Thromboelastograph in Assessing Haemostasis and Drug Efficacy in Essential Thrombocythemia.. *Blood*, **2005**, 106, 4959-4959	2.2	

List of Publications

7	Myeloproliferative Disorders Are Associated with an Increase in Levels of Prothrombotic and Inflammatory Markers Despite Cytoreductive Therapy.. *Blood*, **2006**, 108, 3625-3625	2.2
6	Natural History of Idiopathic Erythrocytosis A Retrospective Case Series Review.. *Blood*, **2006**, 108, 1298-1298	2.2
5	Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.. *Blood*, **2007**, 110, 2543-2543	2.2
4	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. *Blood*, **2018**, 132, 1784-1784	2.2
3	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. *Blood*, **2018**, 132, 1759-1759	2.2
2	Mechanism of thrombosis in essential thrombocythaemia. *Haematologica*, **2006**, 91, 145b	6.6
1	A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.. *Therapeutic Advances in Hematology*, **2022**, 13, 20406207221084487	5.7